BioSpace News Archive

Omnicell, Inc. will release its financial results for the second quarter of 2021 before the open of the market on Thursday, July 29, 2021.

Enrollment in CAReS Study in patients with cancer anorexia on track to deliver first data readout by calendar year-end $10.0 Million of Cash and Cash Equivalents as of May 31, 2021

Summit Therapeutics Inc. is today displaying three preeminent ePosters at the prestigious 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).

Health Logic Interactive Inc. (“Health Logic” or the “Company”) (TSXV: CHIP.H) (OTCPK: CHYPF), is pleased to announce its continued progress towards an 510(k) pre-submission meeting with the United States Food and Drug Administration (the “FDA”) for its diagnostic screening device MATLOC 1 that is anticipated to occur in September 2021 (the “Pre-Submission Meeting”)

NeuroBo Pharmaceuticals, Inc. today announced the result of the elections conducted at its Annual Meeting of Shareholders, held Friday July 9, 2021, during which Hyung Heon Kim and Andrew I. Koven were elected to the Company’s Board of Directors .

The evolution of the urinary self-catheters market is underpinned in large part to the need for devices with high safety profile and ability to mimic the natural micturition.

A vaccines is a biological preparation that helps to fight against any particular diseases and boost up the immunity. A vaccines contain an agent that similar to a disease causing organism and it is made from weakened or killed form of microbes.

The Interatrial shunt is proposed for slightly obtrusive delivery to the heart utilizing trans catheter systems that assist in performing heart procedure.

Rising instances of cancer, also referred to as malignant tumor or malignant neoplasm, has spawned a booming cancer diagnostic market worldwide.

AB Science SA announced that it has been informed by the French National Agency that the measures proposed by AB Science to reinforce patient safety in masitinib trials are acceptable to allow resumption of enrollment in its three ongoing studies; namely, the phase 3 study in mastocytosis, the phase 3 study in amyotrophic lateral sclerosis, and the phase 2 study in COVID-19.